Extracorporeal Membrane Oxygenation Machine Market Size, Share, Opportunities And Trends By Product (ECMO Machine, Software), By Component (Pumps, Oxygenators, Cannul, Accessories), By Modality Outlook (Veno-Venous, Veno-Arterials, Arterio-Venous), And By Geography - Forecasts From 2023 To 2028

  • Published : May 2023
  • Report Code : KSI061615272
  • Pages : 140

An extracorporeal membrane oxygenation machine also referred to as an ECMO machine is a sophisticated medical device that relieves the strain on the heart and lungs by pumping and oxygenating a patient's blood outside of the body. It is similar to a bypass machine and predominantly used in open-heart surgeries. ECMO machine is used in various heart conditions such as acute myocardial infarction, and decompensated cardiomyopathy along with pulmonary disorders such as ARDS and pulmonary embolism. The market for ECMO machines is divided into various segments, including product, component, modality outlook and geographical regions.

Extracorporeal membrane oxygenation machines are used for people who have severe heart and lung diseases, are awaiting a heart transplant, or recovering from a heart transplant. When other attempts at life support have failed, the ECMO machine can also be used as an alternative. Therefore, the rising prevalence of fatal cardiovascular and pulmonary diseases is one of the key drivers of the global extracorporeal membrane oxygenation machine during the projection period. According to the analysis North America and Asia Pacific region are expected to hold a significant market share in the ECMO market during the projection period.

However, the availability of low-cost substitutes, certain risks, high prices and lack of knowledge are likely to obstruct the growth of the global market for extracorporeal membrane oxygenation machines during the projection period. Continuous product innovation, launches and progress in medical technology are providing new opportunities for key market players.

During the anticipation period, rising incidences of cardiovascular and pulmonary diseases will support the growth of the global extracorporeal membrane oxygenation machine market.

ECMO machines relieve the pressure on the lungs and heart by pumping oxygenated blood into their tissues for patients suffering fatal cardiovascular disorders such as heart attack, pulmonary trauma or respiratory infection. Therefore rising incidences of cardiovascular and pulmonary disorders are one of the key factors promoting the growth of the ECMO machine market on a global scale. According to WHO estimates, cardiovascular diseases are the main cause of death with 17.9 million or 32 per cent deaths worldwide in 2019 out of which heart attack and stroke deaths accounted for 85 per cent of these fatalities. WHO also says that 3.23 million people died from chronic obstructive pulmonary disease, the third most common cause of mortality in the world in 2019.

ECMO machines are predominately used for patients growing through open heart surgeries or transplant surgeries. According to the official data, globally around 500,000 open heart procedures are carried out of which 60,000 procedures are carried out in India and 2,00,000 in the United States. 10 per cent of people with coronary artery disease get a coronary artery bypass graft operation. According to UNOS data, a record 3,817 heart transplants were carried out in the United States last year thanks to the efforts of hospitals that conduct transplants and organizations that obtain organs. In 2021, 159 more transplants were done than in 2020, with 513 of those being paediatric heart transplants, up from 413 in 2020.

During the forecast period, North America is anticipated to hold a significant share of the global extracorporeal membrane oxygenation machine market.

North American region is anticipated to hold a substantial market share in extracorporeal membrane oxygenation machines. This region will experience rapid expansion throughout the projection period due to the growing demand for technologically advanced and sophisticated medical devices. ECMO machines are in high demand in markets such as the United States and Canada. This region's market is also expanding as a result of the rising prevalence of heart attacks and pulmonary disorders. According to recent estimates by CDC, In the United States, heart disease is the leading cause of mortality for both sexes and for members of the majority of racial and ethnic groups. Cardiovascular disease claims one life in the United States every 34 seconds claiming the lives of almost 697,000 people in 2020. Every 40 seconds, a heart attack occurs in the United States which shows that 805,000 Americans experience a heart attack each year. Moreover, the presence of a well-established healthcare industry and high healthcare expenditure are also spurring regional demand for ECMO machines. They are becoming more popular among people in this region as a result of rising awareness of the ECMO machines and a growing number of heart surgeries performed in the USA and Canada thereby fueling regional market expansion. In addition, the prevalence of key market players such as LivaNova, Eurosets, Getinge AB, Livanova Plc, Medtronic PLC and others also spur the growth of extracorporeal membrane oxygenation machines in this region.

Market Key Developments

  • In March 2023, LivaNova's Essenz heart-lung machine (HLM) has been given 510(k) approval by the US Food and Drug Administration for use in cardiopulmonary bypass surgeries. The firm will now be allowed to start the commercial launch of the Essenz machine in the US thanks to this permission. Additionally, recently, the Japanese Pharmaceuticals and Medical Devices Agency and Health Canada both gave Essenz HLM their approval.
  • In July 2022, Israeli MedTech company Inspira Technologies is developing the Liby System, a new generation ECMO system with a number of new features and capabilities as well as a novel, colourful graphical representation that improves the visibility, scope, and functionality of data displayed to the medical staff. The rapid-style aerospace-grade aluminium structure of the Liby system is being developed to be both lightweight and highly durable. It will also be equipped with a long battery life, which contributes to the Liby system's suitability for patient mobility within hospitals and for the transportation of patients to hospitals in ambulances.


  • By Product
    • ECMO Machine
    • Software
  • By Component
    • Pumps
    • Oxygenators
    • Cannul
    • Accessories
  • By Modality Outlook
    • Veno-Venous
    • Veno-Arterials
    • Arterio-Venous
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • The Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others

Frequently Asked Questions (FAQs)

2021 has been taken as the base year in the extracorporeal membrane oxygenation machine market.
Prominent key market players in the extracorporeal membrane oxygenation machine market include Medtronic plc, LivaNova, Terumo Cardiovascular Systems Corporation, Nipro Medical Corporation, and Microport Scientific Corporation, among others.
The extracorporeal membrane oxygenation machine market has been segmented by product, component, modality outlook, and geography.
The rising incidences of cardiovascular and pulmonary diseases will support the extracorporeal membrane oxygenation machine market growth.
North America is anticipated to hold a significant share of the extracorporeal membrane oxygenation machine market due to the growing demand for technologically advanced and sophisticated medical devices.


1.1. Market Overview

1.2. Market Definitions

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. ECMO Machine

5.3. Software


6.1. Introduction

6.2. Pumps

6.3. Oxygenators

6.4. Cannul 

6.5. Accessories


7.1. Introduction

7.2. Veno-Venous

7.3. Veno-Arterials

7.4. Arterio-Venous 


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix


10.1. Medtronic plc

10.2. LivaNova

10.3. Terumo Cardiovascular Systems Corporation

10.4. Nipro Medical Corporation

10.5. Microport Scientific Corporation

10.6. Getinge AB

10.7. Xenios AG



Medtronic plc


Terumo Cardiovascular Systems Corporation

Nipro Medical Corporation

Microport Scientific Corporation

Getinge AB

Xenios AG